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Identity 
Note: the chromosome 13q deletion is a relatively 
common finding in chronic myeloproliferative 
disorders and lymphoid neoplasias, including B-cell 
chronic lymphocytic leukemia (CLL), non-Hodgkin's 
lymphoma (NHL) and multiple myeloma (MM). 
Whereas the commonly deleted region comprise a 100-
kb gene-rich segment at the 13q14 chromosome band 
in CLL, the commonly deleted segment in NHL was 
not characterized in detail. 
 
del(13)(q14q21) in NHL (G-banding) - Antonio Cuneo; the 
vertical bar indicates the missing chromosome segment (left); 
del(13)(q14q33) R- banding (right) – Editor. 
Clinics and pathology 
Disease 
B-NHL 
Phenotype/cell stem origin 
Peripheral B-cells at different stages of differentiation. 
Pre germinal centre: small lymphocytic lymphoma 
(SLL), mantle cell lymphoma (MCL). 
Post-germinal centre: marginal zone B-cell lymphoma 
(MZBCL) follicle centre cell lymphoma (FCCL), 
diffuse large cell lymphoma (DLCL). 
Epidemiology 
Incidence. 
SLL: 5-10% of all NHL diagnosed by surgical biopsy. 
MCL: 5-10% of all NHL in western countries. 
MZBCL: 0-15% of NHL, including the extra-nodal 
form the nodal and the splenic form. 
FCCL: 30-40% of NHL. 
DLCL: 30-40% of NHL. 
Clinics 
SLL: low-grade histology, usually running an indolent 
course; survival largely dependent on clinical stage t 
presentation. 
MCL: intermediate-grade histology, poor response to 
therapy, median survival 3-4 years. 
MZBCL: low-grade histology, indolent disease, median 
survival >5 years. 
FCCL: low-grade histology, indolent disease, median 
survival > 5 years. 
DLCL: high grade histology, aggressive disease, 
survival influenced by age, stage at presentation, 
performance status. 
Prognosis 
The significance of 13q- is uncertain because of 
heterogeneity of patients population and histology; a 
low CR rate was described but it is not clear whether 
this depends on its close association with MCL. 
Cytogenetics 
Additional anomalies 
With the notable exception of SLL/CLL the 13q 
deletion is not found as an isolated change in NHL; 
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it was reported as a stemline-associated anomaly in 
most cases having complex karyotypes, suggesting that 
it may represent a relatively early event in the 
cytogenetic history of NHL; the association with other 
anomalies reflects the incidence of the 13q- 
chromosome in distinct histologic subsets: thus it was 
frequently found in karyotypes presenting the 
t(11;14)(q13;q32); many patients with the 
inv(14)(q11q32), associated with T-cell lymphoid 
neoplasias, were found to carry a 13q- chromosome. 
Genes involved and proteins 
Note 
Involved loci: the few characterized cases showed a 
deletion of the D13S319 marker, located between the 
Rb locus and the D13S25 marker; FISH studies were 
performed using probes targeting the Rb locus or the 
loci comprised between Rb and the D13S25 marker. 
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